Acorda is shifting into survival mode. And it’s going to start by axing more than 100 staffers.
PHOTO: Cohen at BIO 2016
One month after a US district court tossed four key patents on its flagship drug Ampyra, leaving it with one to stand on into next year, Acorda $ACOR is chopping 20% of its staff as it scrambles to restructure while gambling that it can field new drugs in short order. Those cuts will fall disproportionately on the company’s R&D staff, CEO Ron Cohen tells me, as Acorda circles its wagons around its two late-stage drugs while conserving its marketing muscle.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.